CD13: A Key Player in Multidrug Resistance in Cancer Chemotherapy.
Oncol Res
; 28(5): 533-540, 2020 Dec 10.
Article
em En
| MEDLINE
| ID: mdl-32532363
Cancer is one of the most serious diseases that are harmful to human health. Systemic chemotherapy is an optimal therapeutic strategy for the treatment of cancer, but great difficulty has been encountered in its administration in the form of multidrug resistance (MDR). As an enzyme on the outer cell surface, CD13 is documented to be involved in the MDR development of tumor cells. In this review, we will focus on the role of CD13 in MDR generation based on the current evidence.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Resistência a Múltiplos Medicamentos
/
Antígenos CD13
/
Resistencia a Medicamentos Antineoplásicos
/
Neoplasias
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article